Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From EQRx, Inc.
EQRx Raises White Flag On Its Low-Cost Drug Business Model
The company is backing out of the development of several clinical-stage assets and will cut 170 positions while it changes its business strategy.
Novartis’s Kisqali Strikes Gold In Adjuvant Early Breast Cancer Setting
The Swiss major’s CDK4/6 inhibitor has met the primary endpoint in a pivotal breast cancer trial earlier than expected, with success in the intermediate risk group representing a $4bn opportunity untapped by rival Eli Lilly.
Novel Anti-Hypertensive Treatment & NSCLC Drug Among New EU Filings
The European Medicines Agency has added five new drugs to its latest monthly list of medicines that are under review for potential EU marketing approval.
Finance Watch: Biopharma Reckoning Brings Restructuring Plans, Consolidation
With cash preservation in mind, Rubius will dissolve, while EQRx, Impel, Cybin and Graphite cut jobs. Meanwhile, Jounce is restructuring and it plans to merge with Redx, yet the dually troubled firms MEI Pharma and Infinity will combine, while VBL will disappear in a reverse merger with Notable Labs.
- Specialty Pharmaceuticals
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.